Reports Q1 revenue $865,000, consensus $5.96M. “CRISPR Therapeutics (CRSP) remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood Makes Surprising Moves by Buying AMD and Selling CRISPR
- ‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital
- Crispr Therapeutics AG: Promising Growth with Casgevy Launch and Innovative Pipeline
- Crispr Therapeutics price target lowered to $80 from $86 at BofA
- Largest borrow rate increases among liquid names